Luminex-Based Diagnostic Test Reduces Unneeded Prostate Biopsies and Improves Detection of Prostate Cancer

In this presentation, Ramy Huber, MSc., research associate, ProteoMediX AG, describes how Luminex xMAP technology was used to develop a novel immunoassay for biomarkers associated with prostate cancer. Learn how the method has the potential to significantly lower the rate of unnecessary prostate biopsies which are negative for cancer by more than 50%. Learn about current issues surrounding prostate cancer diagnosis, Luminex assay development and clinical testing of the new assay.